Published in Anticancer Drugs on June 01, 2006
Phase I Study of Docetaxel and Temsirolimus in Resistant Solid Malignancies | NCT00703625
Cell size and invasion in TGF-beta-induced epithelial to mesenchymal transition is regulated by activation of the mTOR pathway. J Cell Biol (2007) 3.47
Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors. Gastroenterology (2008) 3.04
Evolutionary dynamics of carcinogenesis and why targeted therapy does not work. Nat Rev Cancer (2012) 2.71
Growth factor receptors and related signalling pathways as targets for novel treatment strategies of hepatocellular cancer. World J Gastroenterol (2008) 1.31
Combined analysis of eIF4E and 4E-binding protein expression predicts breast cancer survival and estimates eIF4E activity. Br J Cancer (2009) 1.24
Rapamycin weekly maintenance dosing and the potential efficacy of combination sorafenib plus rapamycin but not atorvastatin or doxycycline in tuberous sclerosis preclinical models. BMC Pharmacol (2009) 1.20
Pharmacokinetic and tumor distribution characteristics of temsirolimus in patients with recurrent malignant glioma. Clin Cancer Res (2007) 1.13
Topical rapamycin inhibits tuberous sclerosis tumor growth in a nude mouse model. BMC Dermatol (2008) 1.12
Cordycepin inhibits protein synthesis and cell adhesion through effects on signal transduction. J Biol Chem (2009) 1.03
In vivo characterization of a polymeric nanoparticle platform with potential oral drug delivery capabilities. Mol Cancer Ther (2008) 0.99
Targeting mTOR pathway: A new concept in cancer therapy. Indian J Med Paediatr Oncol (2010) 0.99
Antitumour efficacy of MEK inhibitors in human lung cancer cells and their derivatives with acquired resistance to different tyrosine kinase inhibitors. Br J Cancer (2011) 0.96
Dual inhibition of EGFR and VEGFR pathways in combination with irradiation: antitumour supra-additive effects on human head and neck cancer xenografts. Br J Cancer (2007) 0.95
Progress in the treatment of neuroendocrine tumors. Curr Oncol Rep (2009) 0.91
Mutational analysis of the PTEN gene and its effects in esophageal squamous cell carcinoma. Dig Dis Sci (2010) 0.87
Impact of rapamycin on liver regeneration. Virchows Arch (2008) 0.87
Treatment of gastrointestinal neuroendocrine tumors with inhibitors of growth factor receptors and their signaling pathways: recent advances and future perspectives. World J Gastroenterol (2008) 0.85
The synergistic effect of everolimus and chloroquine on endothelial cell number reduction is paralleled by increased apoptosis and reduced autophagy occurrence. PLoS One (2013) 0.82
Antagonistic effects of chloroquine on autophagy occurrence potentiate the anticancer effects of everolimus on renal cancer cells. Cancer Biol Ther (2015) 0.80
Immunohistochemical expression of components of the Akt-mTORC1 pathway is associated with hepatocellular carcinoma in patients with chronic liver disease. Dig Dis Sci (2007) 0.78
Interfering with the reconsolidation of traumatic memory: sirolimus as a novel agent for treating veterans with posttraumatic stress disorder. Ann Clin Psychiatry (2013) 0.77
Targeted medical therapy of biliary tract cancer: recent advances and future perspectives. World J Gastroenterol (2008) 0.77
Novel sorafenib-based structural analogues: in-vitro anticancer evaluation of t-MTUCB and t-AUCMB. Anticancer Drugs (2014) 0.76
GASTROENTEROPANCREATIC NEUROENDOCRINE TUMORS (GEP-NETs) - APPROACH TO DIAGNOSIS AND MANAGEMENT. Ann Ib Postgrad Med (2009) 0.75
Sirolimus effects on cancer incidence after kidney transplantation: a meta-analysis. Cancer Med (2015) 0.75
Effects of bufalin on the mTOR/p70S6K pathway and apoptosis in esophageal squamous cell carcinoma in nude mice. Int J Mol Med (2017) 0.75
Interrogating the hidden phosphoproteome. Proteomics (2017) 0.75